Results 281 to 290 of about 113,350 (308)

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang, Pauline Reynier, Antonios Douros, Oriana H. Y. Yu, Robert W. Platt, Kristian B. Filion   +5 more
wiley   +1 more source

One‐year usage patterns of SGLT‐2 inhibitors and GLP‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 972-981, February 2026.
Abstract Aims Real‐world studies of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage.
Louise A. Donnelly, Katyayeni Singh, Rory J. McCrimmon, Ewan R. Pearson   +3 more
wiley   +1 more source

Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study. [PDF]

Eur Heart J
Rea F, Morabito G, Corrao G, Mancia G.
europepmc   +1 more source

SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register‐based randomised trial on prevention of diabetic complications

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1327-1338, February 2026.
Abstract Aims Metformin has hitherto not been proven superior to other type 2 diabetes (T2D) medications for the prevention of organ complications. The aim of this study is to report baseline data and blinded interim analyses in the register‐based randomised clinical trial (RRCT) SMARTEST, which compares metformin and the SGLT2 inhibitor dapagliflozin ...
Jan W. Eriksson, Giovanni Fanni, Martin H. Lundqvist, Stefan Jansson, Karin Rådholm, Sheyda Sofizadeh, Vagia Patsoukaki, Albert Nilsson, Daniel Lindholm, Olov Rolandsson, Anna Norhammar, Elisabet Granstam, Björn Eliasson, Louise Bennet, Johan Sundström   +14 more
wiley   +1 more source

Effectiveness of antihypertensive drugs for secondary prevention of ischaemic stroke: a nationwide historic cohort study. [PDF]

BMJ Open
Perrier J, Gabet A, Olié V, Pariente A, Tzourio C, Bezin J.   +5 more
europepmc   +1 more source

Antihypertensive drugs for hyperuricemia in patients with hypertension: a systematic review and network meta-analysis of Chinese trials. [PDF]

BMC Cardiovasc Disord
Wu J, Di H, Zhang Y, Zeng X.
europepmc   +1 more source

Maximizing blood pressure lowering effects: a review of drug class comparisons and rationale for combination approaches. [PDF]

Front Cardiovasc Med
Yang Y, Wan F, Xu J, Mei Deng H, Pan P.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Molecular imaging in oncology: Current impact and future directions

Ca-A Cancer Journal for Clinicians, 2022
Steven P Rowe, Martin G Pomper
exaly  

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly